Emilio Matt

Corporate Officer/Principal bei MICROSOFT CORPORATION

Technology Services

Health Technology

Aktive Positionen von Emilio Matt

Unternehmen	Position	Beginn	Ende
MICROSOFT CORPORATION	Corporate Officer/Principal	-	-
Alzheimers Drug Discovery Foundation Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr.	Direktor/Vorstandsmitglied	-	-

International

Vereinigte Staaten

Operativ

Corporate Officer/Principal	1
Director/Board Member	1

Sektoral

Technology Services	2
Health Technology	2

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
MICROSOFT CORPORATION	Technology Services

Private Unternehmen	1
Alzheimers Drug Discovery Foundation Alzheimers Drug Discovery Foundation BiotechnologyHealth Technology The Alzheimer's Drug Discovery Foundation (ADDF) is a public charity founded in 1998 by Ronald Steven Lauder, Leonard Alan Lauder, and Howard Fillit. The non-profit company is based in New York, NY. The ADDF is dedicated to accelerating the discovery of drugs to prevent, treat, and cure Alzheimer's disease. The company is the only public charity solely focused on funding the development of drugs for Alzheimer's, using a venture philanthropy model to support research in academia and the biotech industry. The ADDF has awarded over $209 million to fund over 690 Alzheimer's drug discovery programs, biomarker programs, and clinical trials in 19 countries. The CEO is Mark Roithmayr.	Health Technology

Private Unternehmen

Health Technology